Rare diseases
Expansion into new international biotech markets can be challenging. Unfamiliar regulations and licensing, coupled with language and cultural differences, can all be barriers to growth. If you’re considering venturing into Europe and beyond, our easy-to-follow guides, shaped by 30 years of expertise in the rare disease market, will assist you in navigating challenges and gaining a profound understanding of the complexities involved in launching orphan drugs into new markets.
Thought Leadership
The impact of real-world evidence in gaining access to the European orphan drugs market.
News
Sciensus partners with ITN and Genetic Alliance UK for Rare Disease Day
Thought Leadership
Navigating expanded access in Europe: a strategic blueprint for biotech leaders
Blog
Accessing and supporting EU rare disease patients: a quick guide
Blog
Early access programs – benefits, challenges and the Sciensus solution
Case Studies
Developing a comprehensive support program in Europe
Case Studies
How Sciensus supported the launch of a breakthrough therapy in Europe and beyond
Thought Leadership
Strategies for entering the European orphan drugs market
Thought Leadership
Realize your European orphan drug expansion